All News

AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Study on enthesitis response to biologic Rx ⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compared to secukinumab ⭐️ 🔽PASI and DLQI score more in TNFI than Secukinumab 🔰Superiority of TNFi versus secukinumab in regards to active enthesitis Abst#1356 #ACR21 @Rheumnow https://t.co/wdzMYmn8AJ
swethaann23 swethaann23 ( View Tweet)
Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP
Richard Conway RichardPAConway ( View Tweet)
Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
Richard Conway RichardPAConway ( View Tweet)
Real-world data shows no difference between genders in effectiveness of secukinumab in #AnkylosingSpondylitis, for disease activity, global functioning and severity of depression. #Abs0909 #ACR21 @RheumNow https://t.co/2n6Y5ZB1Ot https://t.co/zIMEzHBUrh

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Pipeline

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

d Olga Petryna, MD

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Read Article
⁦@JointMD⁩ shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. ⁦@RheumNow⁩ #acr21 https://t.co/mVw05iFPhF

Links:

TheDaoIndex KDAO2011 ( View Tweet)

PSO.Palmoplantar.jpg

Biologic Use and the Risk of Serious Infection in Psoriasis Patients

d Jack Cush, MD

National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or apremila

Read Article
SI,sacroiliitis,erosion

TICOSPA - Does Treat to Target Work in Spondyloarthritis?

d Jack Cush, MD

Tight-control or treat-to-target (T2T) strategy is advocated in several diseases, but the recent TICOSPA trial in axial spondyloarthritis (axSpA) showed that T2T was not superior to usual care (UC).

Read Article
ICYMI: Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN https://t.co/91FbwCYsmj

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

RheumNow Podcast – Quackademia (10.15.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.

Read Article
ICYMI: Secukinumab (IL-17 inhibitors) can be safely used in HIV spondyloarthritis patients. https://t.co/hpCRJkR9w7 https://t.co/qwbrvGkriX

Links:

Dr. John Cush RheumNow ( View Tweet)
DAPSA PsA measure

Pathways to a Psoriatic Arthritis Diagnosis

d Jack Cush, MD

Ogdie and colleagues have retrospectively analyzed a longitudinal cohort of psoriatic arthritis (PsA) patients, showing that only two-thirds of PsA are diagnosed by rheumatologists, PCPs and dermatologists, with significant differences in what preemptive symptoms were noted by different subspecialties.

Read Article
Secukinumab (IL-17 inhibitors) can be safely used in HIV spondyloarthritis patients. https://t.co/hpCRJkR9w7

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast square

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

d Jack Cush, MD

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.

Read Article
Pregnancies exposed to ixekizumab (from Eli Lilly Global Safety Database) found 193 pts with psoriasis, PsA, or axSpA who were IXE exposed. Live births reported for 53.8 and 61.1% of known outcomes. No congenital malformations seen. https://t.co/M1rvCH81hT

Links:

Dr. John Cush RheumNow ( View Tweet)

psoriatic.PIP_.JPG

Predictors of Inflammatory Arthritis

d Jack Cush, MD

Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was protective in all 4 conditions.

Read Article
Why do they always say larger RCTs are needed? RCT was >1000 and superiority of Bimekizumab to Secukinumab was shown. Maybe it is better to inhibit more than IL17A with added value of IL17F @RheumNow https://t.co/DAwZKxxinM

Links:

Janet Pope Janetbirdope ( View Tweet)

Literature review examined safety of IL-17 inhibitors in 106 controlled RCTs, 40,053 pts. Inflammatory bowel disease was reported in 0.4% of IL-17i Rx patients. (same in 61 uncontrolled RCTs -0.36%). Other AE: diarrhea (2.5%), N/V(0.7%) https://t.co/2wSZQqB1Zs

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: New-Onset IBD & IL-17 Inhibitors: What’s the Risk? https://t.co/zXDQotDiWV Patients w/ inflammatory/autoimmune diseases who initiated treatment w/ IL-17 inhibitors didnt have a higher risk for development of IBD, but only based on the severity of their underlying disease https://t.co/w3IpQkzmn7

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.

×